HighTower Advisors
ENTX icon

HighTower Advisors’s Entera Bio ENTX Stock Holding History

HighTower Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.9K Sell
36,830
-6,310
-15% -$8.86K ﹤0.01% 3723
2025
Q4 		$83.7K Buy
43,140
+25,000
+138% +$58.6K ﹤0.01% 3527
2025
Q3 		$34.8K Sell
18,140
-49,404
-73% -$94.5K ﹤0.01% 3637
2025
Q2 		$128K Buy
67,544
+49,404
+272% +$97.7K ﹤0.01% 3418
2025
Q1 		$30.8K Buy
18,140
+6,310
+53% +$13.7K ﹤0.01% 3489
2024
Q4 		$25.1K Hold
11,830
– – ﹤0.01% 3525
2024
Q3 		$22K Hold
11,830
– – ﹤0.01% 3503
2024
Q2 		$22K Hold
11,830
– – ﹤0.01% 3389
2024
Q1 		$20K Hold
11,830
– – ﹤0.01% 3350
2023
Q4 		$7K Hold
11,830
– – ﹤0.01% 3458
2023
Q3 		$9K Hold
11,830
– – ﹤0.01% 3391
2023
Q2 		$10K Buy
+11,830
New +$10.1K ﹤0.01% 3305

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SEIA
Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

HighTower Advisors's ENTX Position: Q1 2026 in Review

HighTower Advisors reduced its Entera Bio (ENTX) stake by 15% in Q1 2026, selling an estimated $8.86K and leaving 36,830 shares worth $40.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3723.

HighTower Advisors first reported a position in ENTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $128K in Q2 2025. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

  • HighTower Advisors held 36,830 shares of Entera Bio worth $40.9K as of Q1 2026.
  • HighTower Advisors sold 6,310 Entera Bio shares in Q1 2026, an estimated $8.86K.
  • Entera Bio made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3723 holding.
  • HighTower Advisors first reported a position in Entera Bio in Q2 2023 and has held it in 12 quarters since.
  • HighTower Advisors's Entera Bio position peaked at $128K in Q2 2025.
  • 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.